Published in J Invest Dermatol on December 01, 2004
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest (2006) 11.89
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet (2006) 9.56
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest (2006) 4.77
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med (2012) 3.49
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 3.38
Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm (2005) 2.63
Type I interferon: potential therapeutic target for psoriasis? PLoS One (2008) 2.08
The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol (2012) 1.80
Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73
Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest (2006) 1.65
Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest (2006) 1.58
Th17 cells in immunity and autoimmunity. Clin Dev Immunol (2013) 1.40
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest (2008) 1.27
Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br J Dermatol (2011) 1.17
Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus. Infect Immun (2011) 1.13
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol (2010) 1.10
IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts. PLoS Med (2008) 1.04
Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr (2009) 1.04
Ustekinumab. Nat Rev Drug Discov (2009) 1.02
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J Invest Dermatol (2004) 0.94
Progress in spondylarthritis. Progress in studies of the genetics of ankylosing spondylitis. Arthritis Res Ther (2009) 0.94
Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis. Rheumatology (Oxford) (2009) 0.93
P2 purinergic receptor modulation of cytokine production. Purinergic Signal (2007) 0.93
The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep (2010) 0.92
Ustekinumab: differential use in psoriasis. Clin Cosmet Investig Dermatol (2011) 0.91
Generation of a protective T-cell response following coronavirus infection of the central nervous system is not dependent on IL-12/23 signaling. Viral Immunol (2008) 0.90
Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice. J Immunol (2015) 0.89
The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res (2007) 0.84
Central muscarinic cholinergic activation alters interaction between splenic dendritic cell and CD4+CD25- T cells in experimental colitis. PLoS One (2014) 0.83
Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer. J Biomed Biotechnol (2012) 0.82
The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. Arch Immunol Ther Exp (Warsz) (2015) 0.82
Psoriasis: advances in pathophysiology and management. Postgrad Med J (2007) 0.82
Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol (2016) 0.79
Ustekinumab in the therapy of chronic plaque psoriasis. Biologics (2009) 0.79
Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis (2013) 0.79
Immunobiologics in the treatment of psoriasis. Clin Immunol (2007) 0.79
Interleukin-12 to interleukin 'infinity': the rationale for future therapeutic cytokine targeting. Springer Semin Immunopathol (2006) 0.78
Potential role of ustekinumab in the treatment of chronic plaque psoriasis. Biologics (2010) 0.78
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis. Eur J Clin Pharmacol (2016) 0.77
Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol (2009) 0.75
Ustekinumab for the treatment of psoriatic arthritis: an update. Clin Cosmet Investig Dermatol (2014) 0.75
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. Clin Cosmet Investig Dermatol (2009) 0.75
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis. Rheumatol Ther (2015) 0.75
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther (2016) 0.75
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag (2010) 0.75
The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab. PLoS One (2015) 0.75
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting. J Clin Aesthet Dermatol (2015) 0.75
Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study. Clin Rheumatol (2017) 0.75
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
Use of indoor tanning facilities by white adolescents in the United States. Arch Pediatr Adolesc Med (2003) 3.16
Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol (2005) 2.49
Fusobacterium nucleatum induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth. Infect Immun (2004) 2.47
Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol (2008) 2.23
Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol (2009) 2.21
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07
Prognosis of patients with transected melanomas. Dermatol Surg (2013) 2.04
Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol (2004) 1.81
Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat (2009) 1.80
IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol (2009) 1.77
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol (2005) 1.68
Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol (2007) 1.64
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol (2007) 1.62
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59
Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol (2008) 1.58
An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol (2006) 1.54
New viral vaccines for dermatologic disease. J Am Acad Dermatol (2008) 1.50
Oxaliplatin: a review of evolving concepts. Cancer Invest (2002) 1.47
High ultraviolet A protection affords greater immune protection confirming that ultraviolet A contributes to photoimmunosuppression in humans. J Invest Dermatol (2003) 1.47
Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther (2014) 1.42
Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42
Usefulness of flow cytometry in the diagnosis of mycosis fungoides. J Am Acad Dermatol (2007) 1.41
Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol (2005) 1.41
Parvovirus B19-associated systemic lupus erythematosus: clinical mimicry or autoimmune induction? J Rheumatol (2010) 1.39
Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol (2004) 1.36
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol (2009) 1.32
Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem (2014) 1.27
Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol (2011) 1.26
Connections between psoriasis and Crohn's disease. J Am Acad Dermatol (2003) 1.26
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol (2013) 1.20
Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol (2010) 1.16
Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. Infect Immun (2007) 1.16
Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol (2009) 1.15
Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol (2006) 1.14
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther (2005) 1.13
Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol (2009) 1.12
TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol (2002) 1.11
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin (2007) 1.11
Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med (2008) 1.10
Paraneoplastic dermatoses associated with gynecologic and breast malignancies. Obstet Gynecol Surv (2010) 1.09
Ultraviolet immunosuppression: mechanisms and consequences. Dermatol Clin (2006) 1.09
Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol (2002) 1.08
Computerized interactive educational tools used to improve use of sun-protective clothing and sunscreen: a randomized controlled study. Arch Dermatol (2012) 1.08
Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial. Arch Dermatol (2002) 1.07
Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial. Lasers Surg Med (2010) 1.07
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol (2011) 1.06
Consensus guidelines for the management of plaque psoriasis. Arch Dermatol (2012) 1.06
Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders: A Randomized Controlled Study. Arch Dermatol (2012) 1.05
Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf (2011) 1.03
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol (2007) 1.03
Apoptosis mechanisms related to the increased sensitivity of Jurkat T-cells vs A431 epidermoid cells to photodynamic therapy with the phthalocyanine Pc 4. Photochem Photobiol (2008) 1.02
Quantification of human beta-defensin-2 and -3 in body fluids: application for studies of innate immunity. Clin Chem (2007) 1.01
Inhibition of monocytic interleukin-12 production by Candida albicans via selective activation of ERK mitogen-activated protein kinase. Infect Immun (2004) 1.01
Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol (2012) 0.99
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol (2011) 0.99
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat (2006) 0.99
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res (2007) 0.99
Modification of surface properties of biomaterials influences the ability of Candida albicans to form biofilms. Appl Environ Microbiol (2005) 0.99
Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol (2011) 0.98
Factors that affect skin aging: a cohort-based survey on twins. Arch Dermatol (2009) 0.98
Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol (2012) 0.98
Successful treatment of Hailey-Hailey disease with acitretin. J Drugs Dermatol (2007) 0.97
Topical application of green and white tea extracts provides protection from solar-simulated ultraviolet light in human skin. Exp Dermatol (2009) 0.97
The sensitivity of Medicare data for identifying incident cases of invasive melanoma (United States). Cancer Causes Control (2004) 0.97
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol (2011) 0.96